SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently under intense selling pressure as investors react to a deleted social media claim by Michael Burry suggesting that AI startup Anthropic is eroding the company's competitive moat. While the broader community is deeply polarized, with many retail bulls dismissing the narrative as market manipulation and highlighting Palantir's strong government contract fundamentals, the stock is experiencing significant volatility as traders debate whether this represents a long-term re-rating or a temporary discount.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow (NOW) is facing intense selling pressure as investors grapple with growing fears that agentic AI could disrupt the traditional software pricing model and enterprise workflow landscape. Despite management's show of confidence through insider buying and partnerships integrating AI, community sentiment remains deeply polarized between those viewing this sell-off as a generational buying opportunity and traders bracing for further capitulation amid technical breakdowns.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing significant momentum as investors digest a wave of high-profile partnerships, including collaborations with Google on AI infrastructure and a manufacturing deal for Elon Musk's Terafab project. The community is actively debating the stock's massive recent breakout, with bulls pointing to the company's long-term transformation strategy and foundry potential, while some traders remain cautious, closely monitoring option volume and potential volatility following the sharp move.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk (SNDK) remains at the center of investor frenzy, driven by aggressive price target upgrades from analysts who point to an AI-fueled supercycle in NAND memory demand. While some community members celebrate the stock's parabolic climb and speculate on a potential stock split, others are increasingly vocal about bubble risks and potential market manipulation, setting up a sharp divide between those chasing momentum and bears calling for a correction.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is capturing intense community attention as investors debate its potential to become the dominant decentralized AI infrastructure, with many participants actively staking in subnets and advocating for long-term accumulation despite recent market volatility. Market sentiment remains highly polarized, oscillating between those who view it as a high-conviction 'Bitcoin of AI' worth buying on dips and others who express concern regarding its price action and reliance on broader crypto market trends.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy is trending following a preliminary revenue report that highlighted record quarterly shipments and successful testing of a new production line, which the company expects will help scale operations. Community members are actively debating the company's long-term credibility and operational execution, with significant sentiment split between bullish investors expecting a short-squeeze on high short interest and bearish participants focused on recent management performance and pending legal proceedings.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is currently seeing intense market volatility driven by polarizing debate over its growth potential versus high valuation, as investors weigh the stock's role in the photonics and AI hardware revolution against concerns about recent financial reports and insider selling. The community remains sharply divided, with bulls pointing to record order backlogs and hyperscaler demand, while bears focus on revenue misses and the potential for dilution to justify a significant pullback.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is seeing a surge in community discussion as proponents emphasize its historical roots dating back to 2011 and its position as a satirical response to traditional finance. Investors are actively debating its potential for long-term growth by drawing comparisons to the early days of established assets, while the community remains divided between those viewing it as an absurd memecoin and those treating it as a legitimate cultural movement.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing intense market volatility driven by a major short squeeze, as participants debate whether the stock is a high-risk momentum play or fundamentally broken due to significant debt and negative earnings. The community is sharply divided, with bulls pointing to high institutional ownership and squeeze mechanics while bears highlight poor financial health and the risk of further share dilution.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is seeing intense trading activity as investors react to the upcoming April 10, 2026, PDUFA date for its RP1 and nivolumab combination therapy in advanced melanoma. The community is sharply divided, with bulls pointing to the departure of key FDA officials and institutional accumulation, while bears highlight the history of previous CRLs and concerns that the resubmission lacks the necessary clinical data to secure approval.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

@Cytomight hi Cytomight! And @MGK2 YOU NEVER SHARE IP! You license the drug for the indications with all kinds of restrictions on where Madrigal can and can’t distribute the LL. Have a great Labor Day weekend

mitchmiller

StockTwits for iOS

 YOU NEVER SHARE IP! You license the drug for the indications with all kinds of restrictions on where Madrigal can and can’t distribute the LL. Have a great Labor Day weekend

Go CYDY

@MLAB @Cytomight 
You’re the best Bro
Say Madrigal wants Leronlimab for hepatitis, cholecystitis and pancreatitis.  Is that 3 license fees?  Are they all grouped into one license fee?

Robert

 
You’re the best Bro
Say Madrigal wants Leronlimab for hepatitis, cholecystitis and pancreatitis.  Is that 3 license fees?  Are they all grouped into one license fee?

@MGK2 @Cytomight they could do it in one agreement, but I doubt it! More than likely as Madrigal and CYDY continue to prove efficacy in certain indications; agreements are likely to be one indication at a time. Sort of like Proof first than agreement is next! I hope that helps

 they could do it in one agreement, but I doubt it! More than likely as Madrigal and CYDY continue to prove efficacy in certain indications; agreements are likely to be one indication at a time. Sort of like Proof first than agreement is next! I hope that helps

@MLAB @Cytomight 
Two indications puzzle me
1) HCC HepatoCellular Carcinoma 
Liver cancer
Right up Madrigals alley given that it is all liver related

2) HIV in patients with MASH
Rezdiffra doesn’t treat HIV, but could a combination LL + rezdiffra be used to treat HIV patient with MASH?

 
Two indications puzzle me
1) HCC HepatoCellular Carcinoma 
Liver cancer
Right up Madrigals alley given that it is all liver related

2) HIV in patients with MASH
Rezdiffra doesn’t treat HIV, but could a combination LL + rezdiffra be used to treat HIV patient with MASH?

@MGK2 @Cytomight Hey MGK2, you bring up some interesting points. The first one regarding just liver disease seems straight forward to me at least on the surface. If LL and Madrigal’s drug in combination kicks ass over their monotherapy, then no question we have a license deal that may expand their current indication from 315K patients to something more. 
Regarding HIV/Nash it’s very possible that the Liver docs will be involved in treating that population and consult with which ever physician is treating the HIV patient. The sales force for Madrigal can educate the Liver docs on the strengths of LL in both disease states. IMO, this sits very well with Madrigal to add more value to their Liver providers!

 Hey MGK2, you bring up some interesting points. The first one regarding just liver disease seems straight forward to me at least on the surface. If LL and Madrigal’s drug in combination kicks ass over their monotherapy, then no question we have a license deal that may expand their current indication from 315K patients to something more. 
Regarding HIV/Nash it’s very possible that the Liver docs will be involved in treating that population and consult with which ever physician is treating the HIV patient. The sales force for Madrigal can educate the Liver docs on the strengths of LL in both disease states. IMO, this sits very well with Madrigal to add more value to their Liver providers!

@MGK2 @Cytomight regarding Liver Cancer! We are aware of Scott Kelly’s comment of; “ We are an Oncology company “ We may or may not be, but I see any and all Oncology indications being separated from other indications. 
I said it this before and MGK has also stated that we may use Madrigal as a source of non-dilutive funding for projects outside of the Nash and NASH/HIV indications. 
IMO, Madrigal buys the rights or licenses the rights for LL’s use in Nash and NASH/HIV. They run the trials required for FDA approval in those indications and CYDY uses that funding for Oncology trials and whatever else we feel is important. 
Please note that the licensing deal is transferable to another BP that might buyout CYDY for all of the other indications. Madrigal keeps the rights for NASH and NASH/HIV and pays the annual Licensing fee or royalties or whatever the arrangement was with CYDY to the new buyer of CYDY. It’s attractive to the new BP that buys CYDY, because they get an instant ROI

 regarding Liver Cancer! We are aware of Scott Kelly’s comment of; “ We are an Oncology company “ We may or may not be, but I see any and all Oncology indications being separated from other indications. 
I said it this before and MGK has also stated that we may use Madrigal as a source of non-dilutive funding for projects outside of the Nash and NASH/HIV indications. 
IMO, Madrigal buys the rights or licenses the rights for LL’s use in Nash and NASH/HIV. They run the trials required for FDA approval in those indications and CYDY uses that funding for Oncology trials and whatever else we feel is important. 
Please note that the licensing deal is transferable to another BP that might buyout CYDY for all of the other indications. Madrigal keeps the rights for NASH and NASH/HIV and pays the annual Licensing fee or royalties or whatever the arrangement was with CYDY to the new buyer of CYDY. It’s attractive to the new BP that buys CYDY, because they get an instant ROI